Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Oncogene|January 28, 2005
The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleusMatthew K Summers, John Bothos, Thanos D HalazonetisOncogene|October 17, 2003
The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chainsJohn Bothos, Matthew K Summers, Monica Venere, et al.Cancer Research|August 3, 2005
Human LATS1 is a mitotic exit network kinaseJohn Bothos, Robyn L Tuttle, Michelle Ottey, et al.Molecular Cancer Research : MCR|January 4, 2008
Defective in mitotic arrest 1/ring finger 8 is a checkpoint protein that antagonizes the human mitotic exit networkRobyn L Tuttle, John Bothos, Matthew K Summers, et al.Cancer Research|November 13, 2003
Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancerGeorge Mariatos, John Bothos, Panayotis Zacharatos, et al.Structure (London, England : 1993)|September 10, 2003
Crystal structure of a human Mob1 protein: toward understanding Mob-regulated cell cycle pathwaysElena S Stavridi, Kimberly G Harris, Yentram Huyen, et al.Journal of Clinical Pharmacology|August 8, 2013
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumorsYan Xin, Denise Jin, Stephen Eppler, et al.Annals of Hematology|March 28, 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndromeGuillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignanciesRavi Salgia, Premal Patel, John Bothos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2022
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung CancerRoy S Herbst, Margarita Majem, Fabrice Barlesi, et al.Pageof 2